This study is for adults whose aggressive lymphoma has returned or not responded to prior treatment. It compares a new two-drug combination (loncastuximab tesirine plus rituximab) against standard immunochemotherapy. The main goal is to see which treatment better delays the cance…
Phase: PHASE3 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC